Navigation Links
Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion
Date:3/17/2008

nd Industries common stock are encouraged to consult with their financial advisors regarding the specific implications of selling their common stock on or before the distribution date.

Currently, there is no public market for Hillenbrand, Inc. (Batesville Holdings) common stock. Hillenbrand, Inc. common stock has been approved for listing on the NYSE under the symbol "HI." The company anticipates that trading in Hillenbrand, Inc. common stock will commence on a "when issued" basis March 19, 2008. Trading on a "when issued" basis means that investors may purchase and sell shares of Hillenbrand, Inc. common stock up to and through the distribution date, but these transactions will not settle until after the distribution date.

On the first trading day following the distribution date, "when issued" trading will end and "regular way" trading will begin for Hillenbrand, Inc. common stock. Neither Hillenbrand Industries (Hill-Rom Holdings) nor Batesville Holdings (Hillenbrand, Inc.) can predict the trading price for their common stock before or following the distribution.

As previously announced, the separation remains subject to favorable market conditions, effectiveness of the Form 10 registration statement with the SEC, completion of necessary debt refinancing and other customary conditions. As previously disclosed, the company has already received a favorable tax ruling from the U.S. Internal Revenue Service (IRS). The Form 10 is expected to be declared effective later in the day on March 17, 2008.

The information statement is available on the SEC website at http://www.sec.gov and also can be viewed on the Hillenbrand website at http://www.hillenbrand.com .

ABOUT HILLENBRAND INDUSTRIES, INC.

Hillenbrand Industries is organized into two operating companies serving the health care and funeral services industries.

Hill-Rom
'/>"/>

SOURCE Hillenbrand Industries, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Hillenbrand Industries, Inc. Announces Early Tender Results of its Pending Any and All Cash Tender Offer for its 4.50 Percent Senior Notes Due 2009
2. Hillenbrand Releases Investor Roadshow Materials and Updated Financial Guidance Related to Separation Of Hill-Rom and Batesville Casket
3. Hillenbrand Industries, Inc. Announces Any and All Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009
4. Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation
5. Hillenbrand Industries Announces Second Quarter 2008 Dividend
6. Hillenbrand Industries Announces Fourth Quarter 2007 Dividend
7. R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries
8. Herley Industries, Inc. Second Quarter Earnings Release and Conference Call Notice
9. China Bionanometer Industries Corporation Announces New Products for China
10. Herley Industries Announces the Passing of Its Former President
11. Communications & Power Industries Completes Acquisition of Malibu Research Associates

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Study in mice reports success with drugs that in...lthDay News) -- Two drugs used to treat breast can... mice, according to a new study. , The drugs al...vagina, and prevented the onset of cancer in mice ...drug fulvestrant and the breast cancer/osteoporosi...
(Date:11/9/2009)... Plavix helped men and women almost equally, stud...News) -- The widely used clot-dissolving drug Plav...in men, an analysis of major clinical trials has f...confident in treating both men and women with this... director of cardiovascular thrombosis at New York...
(Date:11/9/2009)... , Networking is everybod...s it means Money. StaffingClub.com enables Recruit...of contacts to connect, share, communicate and clo... Seekers to post their profiles and network with r...mber 9, 2009 -- Current Job Market forces everyone...
(Date:11/9/2009)... Therapy to improve letter formation could boost ... Nov. 9 (HealthDay News) -- Autistic children are ...g trouble forming letters, than those without auti...8 children, aged 8 to 13. Half of the study partic...e children scored within the normal range for perc...
(Date:11/9/2009)... Rabbits implanted with new cells regained sexual...v. 9 (HealthDay News) -- Researchers were able to ...nises by growing new penile tissue in the lab and ...human application is a ways off, researchers say t... erectile dysfunction in men. , "We were able t...
Breaking Medicine News(10 mins):Health News:Breast Cancer Drugs May Fight Cervical Cancer, Too 2Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3
...ffected the dental health of the expectant mother....ammations can lead to a condition of preeclampsia ...ic dental inflammation and periodontal infection, ...moking, etc. The basic reason for setting in the d...
...nic, progressive disorder where there is a loss of...rug // alendronate if taken daily for 10 years can...ugs, such as alendronate, have been used for years...he drug for the next two years. Then for the next ...
...that fetal cell transplantation for patients with ...id of their medications altogether.// Parkinso... impairs mobility. Patients with Parkinson’s lack ...st dopamine-producing cells to help restore moveme...
...ommon sleep disorder leaves nearly millions groggy...is that // the tricks they do to get to sleep may ...alists say as we age, biological changes gradually...to do is to cut out caffeine after noon and to ski...
... recent study researchers say annual flu vaccines ... on // hospitalizations, respiratory tract infecti...pecially true for children who received an inactiv...r children under age 2 who received the inactivate...
...Society's 140th Midwinter Meeting that begins in U...orld over can take a peek to some very innovative ...isplay there. The convention is also one of the la...s that automatically dispenses toothpaste, and a c...
Other Medicine News:
(Date:11/10/2009)...ass. and TOKYO, Nov. 10 Ironwood P...y announced that they have entered into an agreeme...and commercialize the investigational compound lin...es, Taiwan, and Thailand. Linaclotide is currently...tes for the treatment of irritable bowel syndrome ...
(Date:11/9/2009)...Ala., Nov. 9 Surgical Ca... host an investor conference call at 11:00 a.m. Ea...s its 2009 third quarter operating results. A 30-... following the conclusion of the conference call. ...h/20080812/CLTU111LOGO ) ,, Please go to SCA...
(Date:11/9/2009)...s., Nov. 9 Hologic, Inc....ing developer, manufacturer and supplier of premiu...l products dedicated to serving the healthcare nee...ourth quarter and fiscal year ended September 26, ...rd of Directors has promoted Robert Cascella to Ch...
Breaking Medicine Technology:Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 2Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 2Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 4Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 5Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 6Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 7Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 8Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 9Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 10Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 11Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 12Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 13Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 14Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 15Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 16Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 17Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 18Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 19Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 20Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 21Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 22Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 23Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 24Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 25Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 26Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 27Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 28VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 1VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 5nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 1nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 2nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 3nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 4ReStart DC Launches Life Saving Public Access Defibrillation Program 48583 1ReStart DC Launches Life Saving Public Access Defibrillation Program 48583 2ReStart DC Launches Life Saving Public Access Defibrillation Program 48583 3
... 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq:ACAD) ... Phase II schizophrenia co-therapy trial with ACP-...erse agonist. The trial,evaluated ACP-103 co-thera...ommonly prescribed atypical antipsychotic drug, or.... The co-therapy,arms with ACP-103 demonstrated st...
...ire-FirstCall/ -- La Jolla,Pharmaceutical Company ... data for the Phase 3 trial of Riquent(R) (abetimu...rythematosus,("lupus" or "SLE"). The updated analy...s a definitive and significant dose response,betwe...compared,with placebo (p=0.0001). These interim da...
Other Medicine Technology:Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 2Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 3Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 4Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 5Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 6La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
MG-1000
...R offers a broad range of applications. Many funct...ration. For the height adjustment, the table is eq...to its uncomplicated handling, MERKUR can be used ...le manner. Furthermore, a comprehensive range of a...
MAQUET Orthostar II
...artner when radiological examinations or intervent... an intervention. Due to the motorised longitudina...Enduro provides optimum working conditions in exam...l coupling points ensure that the table can be ext...
Medicine Products: